Has Thrishala Reddy Kasireddy, MD received payments from drug or device companies?

Yes. Drug and device makers reported $892 in general payments to Thrishala Reddy Kasireddy, MD across 37 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Thrishala Reddy Kasireddy, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Thrishala Reddy Kasireddy, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Thrishala Reddy Kasireddy, MD

Hospitalist · Slidell, LANPI 1740956622

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 37 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations.

$892in general payments, 2019–2025

Across 37 payments — averaging $24.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

E.r. Squibb & Sons, L.L.C.$168
AstraZeneca$151
Actelion Pharmaceuticals US, Inc.$122
Boston Scientific$114
AbbVie$73
Novo Nordisk$63
plus $202 from 7 others

What the payments were for

Food & beverage$892100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
E.r. Squibb & Sons, L.L.C.	11	$168
AstraZeneca(2 entities)	8	$151
Actelion Pharmaceuticals US, Inc.	1	$122
Boston Scientific	1	$114
AbbVie	3	$73
Novo Nordisk	3	$63
Boehringer Ingelheim	3	$55
Fresenius Kabi USA, LLC	2	$42
Incyte Corporation	1	$28
Pfizer	1	$21
Takeda Pharmaceuticals U.S.A., Inc.	1	$20
Alcresta Therapeutics, Inc.	1	$19
Bayer	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$892 in reported general payments places this provider in the 80th percentile of 301 hospitalist providers in Louisiana.

See all hospitalist providers in Louisiana →

Medicare billing

Part B allowed, 2024

$21,161

Medicare patients

Services billed

199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Prednisone	16	$77
Amlodipine Besylate	13	$76
Furosemide	15	$57

Paid to pharmacies, not to this prescriber.